| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
San Diego, CA, November 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (Inhibrx or the Company) today reported financial results for the third quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. |
| 28 Sep 2026 |
8-K: Regulation FD Disclosure
INHIBRX Investor Presentation Innovation Driven Outcomes Focused • |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
P R OP R IE TAR Y AN D C ON FID E N TI A L; N OT FOR D IS TR IB U TION INBRX-106 Investor Overview September 2026 |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical tr... |
| 16 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of July 15, 2026, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 30... |
| 15 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
SAN DIEGO, June 15, 2026/PRNewswire/ – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that th... |
| 03 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Inhibrx Biosciences, Inc. (the “Company”) was held on June 3, 2026 at 10:00 a.m. Pacific Time online in a virtual format. Of the Company’s 14,607,286 shares of common stoc... |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
San Diego, CA, May 14, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. |
| 11 May 2026 |
8-K: Regulation FD Disclosure; Other Events
INHIBRX Investor Presentation Innovation Driven Outcomes Focused |
| 21 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
INHIBRX Investor Presentation Innovation Driven Outcomes Focused |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
San Diego, CA, March 19, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "1... |
| 23 Feb 2026 |
8-K: Regulation FD Disclosure
INHIBRX Investor Presentation Innovation Driven Outcomes Focused |
| 16 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program |
| 14 Nov 2025 |
8-K: Results of Operations and Financial Condition
San Diego, CA, November 14, 2025 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the third quarter of 2025. Following the completion of the sale of INBRX-101 (the “101 Transact... |
| 23 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
INHIBRX Investor Presentation Innovation Driven Outcomes Focused |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
San Diego, CA, August 13, 2025 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2025. Following the completion of the sale of INBRX-101 (the “101 Transacti... |
| 28 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Inhibrx Biosciences, Inc. (the “Company”) was held on May 28, 2025 at 10:00 a.m. Pacific Time online in a virtual format. Of the Company’s 14,475,904 shares of common stoc... |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
San Diego, CA, May 14, 2025 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the “... |
| 01 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 1, 2025, Inhibrx Biosciences, Inc. (the “Company”) announced the appointment of David J. Matly, M.B.A. as President, effective April 1, 2025, adding to his current role as Chief Commercial and Business Development Officer. Mark ... |
| 17 Mar 2025 |
8-K: Results of Operations and Financial Condition
San Diego, CA, March 17, 2025 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhi... |
Loading...